Nadim Ahmed's most recent trade in Cullinan Oncology Inc was a trade of 12,529 Common Stock done at an average price of $8.5 . Disclosure was reported to the exchange on Feb. 25, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Cullinan Oncology Inc | Nadim Ahmed | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 8.53 per share. | 25 Feb 2025 | 12,529 | 430,621 | - | 8.5 | 106,872 | Common Stock |
| Cullinan Oncology Inc | Nadim Ahmed | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Feb 2025 | 360,000 | 360,000 | - | - | Stock Option (Right to Buy) | |
| Cullinan Oncology Inc | Nadim Ahmed | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Feb 2025 | 180,000 | 443,150 | - | 0 | Common Stock | |
| Cullinan Oncology Inc | Nadim Ahmed | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 11.87 per share. | 24 Dec 2024 | 8,400 | 263,150 | - | 11.9 | 99,708 | Common Stock |
| Cullinan Oncology Inc | Ahmed Nadim | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Feb 2024 | 320,000 | 320,000 | - | - | Stock Option (Right to Buy) | |
| Cullinan Oncology Inc | Ahmed Nadim | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Feb 2024 | 160,000 | 271,550 | - | 0 | Common Stock | |
| Cullinan Oncology Inc | Ahmed Nadim | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 9.24 per share. | 26 Dec 2023 | 4,272 | 111,550 | - | 9.2 | 39,473 | Common Stock |
| Cullinan Oncology Inc | Nadim Ahmed | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 11.40 per share. | 28 Jun 2023 | 759 | 115,822 | - | 11.4 | 8,653 | Common Stock |
| Cullinan Oncology Inc | Nadim Ahmed | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 9.15 per share. | 23 May 2023 | 707 | 116,581 | - | 9.1 | 6,469 | Common Stock |
| Cullinan Oncology Inc | Nadim Ahmed | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 10.59 per share. | 25 Apr 2023 | 716 | 117,288 | - | 10.6 | 7,582 | Common Stock |
| Cullinan Oncology Inc | Nadim Ahmed | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 10.51 per share. | 23 Mar 2023 | 706 | 118,004 | - | 10.5 | 7,420 | Common Stock |
| Cullinan Oncology Inc | Nadim Ahmed | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Feb 2023 | 211,000 | 211,000 | - | - | Stock Option (Right to Buy) | |
| Cullinan Oncology Inc | Nadim Ahmed | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Feb 2023 | 109,000 | 118,710 | - | 0 | Common Stock | |
| Cullinan Oncology Inc | Nadim Ahmed | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 10.90 per share. | 30 Jun 2022 | 1,620 | 9,710 | - | 10.9 | 17,658 | Common Stock |
| Cullinan Oncology Inc | Nadim Ahmed | Director, President and CEO | Purchase of securities on an exchange or from another person at price $ 12.40 per share. | 06 Jun 2022 | 8,090 | 8,090 | - | 12.4 | 100,316 | Common Stock |
| Cullinan Oncology Inc | Nadim Ahmed | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Mar 2022 | 215,000 | 215,000 | - | - | Performance Stock Unit | |
| Cullinan Oncology Inc | Nadim Ahmed | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Oct 2021 | 2,710,000 | 2,710,000 | - | - | Stock Option (Right to Buy) | |
| Bristol-Myers Squibb | Nadim Ahmed | EVP and President, Hematology | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Dec 2020 | 14,946 | 46,549 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb | Nadim Ahmed | EVP and President, Hematology | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Dec 2020 | 14,946 | 0 | - | - | Restricted Stock Units | |
| Bristol-Myers Squibb | Nadim Ahmed | EVP and President, Hematology | Payment of exercise price or tax liability using portion of securities received from the company at price $ 62.03 per share. | 31 Dec 2020 | 7,660 | 38,889 (0%) | 0% | 62.0 | 475,150 | Common Stock, $0.10 par value |
| Bristol-Myers Squibb | Nadim Ahmed | EVP and President, Hematology | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Dec 2020 | 6,594 | 34,983 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb | Nadim Ahmed | EVP and President, Hematology | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Dec 2020 | 6,594 | 19,782 | - | - | Restricted Stock Units | |
| Bristol-Myers Squibb | Nadim Ahmed | EVP and President, Hematology | Payment of exercise price or tax liability using portion of securities received from the company at price $ 62.18 per share. | 02 Dec 2020 | 3,380 | 31,603 (0%) | 0% | 62.2 | 210,168 | Common Stock, $0.10 par value |
| Bristol-Myers Squibb | Nadim Ahmed | EVP and President, Hematology | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Oct 2020 | 4,650 | 0 | - | - | Restricted Stock Units | |
| Bristol-Myers Squibb | Nadim Ahmed | EVP and President, Hematology | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Oct 2020 | 4,650 | 30,680 (0%) | 0% | 0 | Common Stock, $0.10 par value | |
| Bristol-Myers Squibb | Nadim Ahmed | EVP and President, Hematology | Payment of exercise price or tax liability using portion of securities received from the company at price $ 58.45 per share. | 30 Oct 2020 | 2,291 | 28,389 (0%) | 0% | 58.5 | 133,909 | Common Stock, $0.10 par value |